Russian Heart Failure Journal 2008year Levels of serotonin in blood and platelets of patients with CHF


To access this material please log in or register

Register Authorize
2008/

Levels of serotonin in blood and platelets of patients with CHF

Nigmatullina R. R., Kirillova V. V., Dzhordzhikiya P. K, Kudrin V. S., Klodt P. M.

Keywords:

DOI:

Urgency. The serotonin system plays an important role in pathogenesis of cardiovascular diseases. However the role of serotonin (5-НТ) in development and progression of CHF is not studied. Aim. To measure plasma and platelet levels of 5-НТ and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) in patients with CHF and to evaluate the relationship of these levels with severity of morpho-functional changes in the myocardium. Materials and methods. Concentrations of 5-HT in plasma and platelets and 5-hydroxyindoleacetic acid (5-HIAA) in plasma were measured using the method of high-performance liquid chromatography with electrochemical detection in 23 CHF patients with different morpho-functional alterations of the myocardium. Results. All patients with CHF had increased 5-HT concentrations in plasma and platelets. The highest platelet levels of 5-HT were found in patients with isolated LV diastolic dysfunction (DD). Concentration of the 5-HT metabolite 5-HIAA was increased in patients with DD and LV hypertrophy and in patients with DD and systolic dysfunction. Therefore synthesis and metabolism of 5-HT are changed in CHF in relation to morpho-functional alterations of the myocardium.
  1. Brum PC, Rolim NP, Bacurau AV, Medeiros A.. Neurohumoral activation in heart failure: the role of adrenergic receptors. An Acad Bras Cienc. 2006;78(3):485-503.
  2. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415(6868):206-212.
  3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
  4. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;271(18):1450-1456.
  5. Vanhoutte P.M. Cardiovascular effects of serotonin. J Cardiovasc Pharmacol. 1987;10(Suppl 3):S8-11.
  6. Côté F, Fligny C, Fromes Y et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med. 2004;10(5):232-238.
  7. Puri VK, Verma M, Saxena AK, Shanker K. Platelet serotonergic mechanisms in ischaemic heart disease. Thromb Res. 1990;57(3):445-451.
  8. Cooper JR, BloomFE, Roth RH. Serotonin (5-hydroxytryptamine), histamine and adenosine. In: The Biochemical Basis of Neuropharmacology. Oxford University Press, New York 2003; 271-320.
  9. Tyce GM. Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16(Suppl 3):51-57.
  10. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J. 1995;22(1):13-19.
  11. Pakala R, Benedict CR. Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med. 1998;131(6):527-537.
  12. Suhara T, Sudo Y, Yoshida K et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet. 1998;351(9099): 332-335.
  13. Gillis CN, Pitt BR. The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol. 1982;44:269-281.
  14. Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de I’Infarctus du Myocarde (ECTIM). Circulation. 2002;105(25):2943-2945.
  15. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36.
  16. Мустафин А.А., Нигматуллина Р.Р., Миролюбов Л.М. и др. Роль серотонинэргической системы в формировании легочной артериальной гипертензии у детей с врожденными пороками сердца. Клиническая физиология кровообращенияю 2007;2:42-46.
  17. Ashton JH, Benedict CR, Fitzgerald C et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986;73(3):572-578.
  18. Golino P, Piscione F, Willerson JT et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324(10):641-648.
  19. Noble M, Drake-Holland AJ. Evidence for a role of serotonin in inhibition of coronary arterial thrombosis in dog and man. Clin Physiol Biochem. 1991; 8(Suppl 3):50-55.
  20. Herving TA, Farstad M. Human blood platelet serotonin studies in vitro: endogenous serotonin may stimulate thrombin-induced serotonin release in stored platelets. Platelets 1996;7(1-2):53-57.
  21. Farstad M. The role of blood platelets in coronary atherosclerosis and thrombosis. Scand J Clin Lab Invest. 1998;58(1):1-10.
  22. Greenberg BD, Tolliver TJ, Huang SJ et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet. 1999;88(1):83-87.
  23. Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Témoins de l’Infarctus du Myocarde (ECTIM). Circulation. 2002;105(25):2943-2945.
  24. Whyte EM, Pollock BG, Wagner WR et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geratic depression. Am J Psychiatry. 2001;158(12):2074-2076.
  25. Tyrer SP, Marshall EF, Griffiths HW. The relationship between respons to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(5):797-805.

To access this material please log in or register

Register Authorize
Ru En